Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa

NCT04919473 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

11

Enrollment

INDUSTRY

Sponsor class

Conditions

Retinitis Pigmentosa
Retinal Diseases
Retinal Degeneration

Interventions

BIOLOGICAL: Gene Therapy product:vMCO-I

Sponsor

Nanoscope Therapeutics Inc.